Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 680 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.
Neores mission is to improve neonatal ventilation to save more preterm infants from death and comorbidities. Their work in this field has led to the development of rPAP, the first novel resuscitation system in more than 30 years.
Recurrent aphthous ulcers (RAS) are mouth ulcers that can last for more than a week at each occasion and during that period patients often suffer and need sick leave. About 80% of all patient’s state that the pain from RAS is the main symptom. The innovative oral patch (MO45A) shields the ulcer giving instant pain relief and improves healing primarily through it´s extensive hygroscopic effect.
QureTech Bio develops new first-in-class antibacterial agents to combat infectious diseases and the occurrence of antibiotic resistance. This is done either by a direct antimicrobial effect or by potentiating existing antibiotics and making them more effective without causing resistance.
